drugset
drugset / Trial / NCT02751996

A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV

NCT02751996 ↗

Phase 2 Completed 80 enrolled F-star Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus

Timeline

Start
2016-05
Primary completion
2020-02-10
Completion
2020-02-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Inarigivir soproxil Small molecule 25 mg —
Comparator Inarigivir soproxil Small molecule 50 mg —
Comparator Inarigivir soproxil Small molecule 100 mg —
Comparator Inarigivir soproxil Small molecule 200 mg —
Comparator Tenofovir Small molecule 300 mg —

Indications

hepatitis B virus infection